Leucocyte adhesion deficiency <scp>III</scp> in a mixed‐breed dog

Hugo, TB; Heading, K. L.

doi:10.1111/avj.12206

Cited by 9 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Possible leukocyte adhesion defects (LADs) were not assessed in our dogs and therefore cannot be eliminated. However, persistent leukocytosis has been reported as a uniform feature in LAD patients and because IWHs with recurrent BP all had normal leukocyte counts, LAD was considered unlikely …”

Section: Discussionmentioning

confidence: 99%

Recurrent bacterial pneumonia in Irish Wolfhounds: Clinical findings and etiological studies

Viitanen

Lappalainen

Koho

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Increased incidence of bacterial pneumonia (BP) has been reported in Irish Wolfhounds (IWHs), and recurrence of BP is common. The etiology of recurrent pneumonia in IWHs is largely unknown. Objectives To describe clinical findings in IWHs with recurrent BP and investigate possible etiologies. Animals Eleven affected IWHs, 25 healthy IWHs, 28 healthy dogs of other Sighthound breeds, and 16 healthy dogs of other breeds. Methods Prospective cross‐sectional observational study. All affected IWHs underwent thorough clinical examinations including thoracic radiographs, thoracic computed tomography, electron microscopic evaluation of ciliary structure, and bronchoscopy and bronchoalveolar lavage fluid (BALF) cytology and culture. Serum and BALF immunoglobulin concentrations were measured using an ELISA method, and peripheral blood lymphocyte subpopulations were analyzed using flow cytometry. Esophageal function was assessed by fluoroscopy (n = 2). Results Median age of onset was 5.0 years (range, 0.4‐6.5 years), and when presented for study, dogs had experienced a median of 5 previous episodes of BP (range, 2‐6). The following predisposing factors to BP were detected: focal bronchiectasis (10/11), unilateral (2/9) and bilateral (1/9) laryngeal paralysis, and esophageal hypomotility (2/2). Local or systemic immunoglobulin deficiencies or primary ciliary defects were not detected. Conclusions and Clinical Importance Recurrent BP affects mostly middle‐aged and older IWHs without any evident immune deficit or primary ciliary defects. Focal BE was a frequent finding in affected dogs and likely contributed to the development of recurrent respiratory infections. Laryngeal and esophageal dysfunction identified in a minority of dogs may contribute to recurrent BP.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent bacterial pneumonia in Irish Wolfhounds: Clinical findings and etiological studies

Viitanen

Lappalainen

Koho

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…B. Meloxicam, werden als antiinflammatorische Medikamente eingesetzt. In einem Fallbericht wurde eine Katze mit FIP (Diagnosestellung: IHC) mit Meloxicam (0,05 mg/kg, q24h, PO) über einen Zeitraum von 119 Tagen in Kombination mit zusätzlicher unterstützender Therapie behandelt und überlebte 787 Tage 29 . NSAIDs dienen jedoch lediglich zur Unterdrückung der Symptome und können FIP nicht heilen.…”

Section: Symptomatische Therapieunclassified

Optionen zur Therapie der felinen infektiösen Peritonitis – früher und heute

Krentz,

Bergmann,

Felten

et al. 2023

Tierarztl Prax Ausg K Kleintiere Heimtiere

View full text Add to dashboard Cite

ZusammenfassungDie feline infektiöse Peritonitis (FIP) ist eine der häufigsten Infektionskrankheiten bei Katzen und verläuft unbehandelt tödlich. Bisher gibt es in Deutschland keine legal verfügbare wirksame Therapie. Therapieoptionen reichen von der symptomatischen Therapie (z. B. Glukokortikoide, Propentofyllin) über immunmodulatorische Ansätze (z. B. Interferone, Polyprenyl-Immunstimulanz) bis hin zur antiviralen Therapie mit einem Protease-Inhibitor (z. B. GC376) oder Nukleosid-Analoga (z. B. GS-441524, Remdesivir). Die symptomatische Therapie führt nicht zur Heilung der FIP, sondern nur zu einer kurzzeitigen Verbesserung der klinischen Symptome bei wenigen Katzen. Auch eine immunmodulatorische Therapie stellte sich als wenig erfolgversprechend heraus. Die antiviralen Medikamente GS-441524 und GC376 waren in mehreren Studien hochwirksam und konnten das Leben vieler an FIP erkrankten Katzen retten. Beide Wirkstoffe sind aktuell in Deutschland nicht zugelassen und können von Tierärzten nicht legal angewendet werden. Katzen dürfen aktuell nur in wenigen Ländern (z. B. Großbritannien und Australien) legal mit GS-441524 therapiert werden. GS-441524 wird daher von Katzenbesitzern in vielen anderen Ländern über den Schwarzmarkt bestellt und in Eigenregie angewendet. Dieser Artikel gibt eine Übersicht über verfügbare Therapieoptionen und einen Ausblick zur legalen Anwendung wirksamer antiviraler Medikamente.

show abstract

“…In dogs, two forms of LAD (LAD I, also called canine LAD I (CLAD I), and LAD III or CLAD III) have been described. Type I, which is caused by a mutation of ITGB2 encoding integrin subunit beta 2 (CD18), was detected in Irish Setters and the closely related Irish Red and White Setter breeds (Gu et al 2004); type III, caused by a mutation of Kindlin 3 (also called FERMT3) and encoding kindling 3 protein (also called fermitin family member 3) has been described in German Shepherd and in a German Shepherd × Rottweiler mongrel (Hugo and Heading 2014).…”

Section: Severe Combined Immunodeficiency Diseases and Leukocyte Adhementioning

confidence: 99%

Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies

Świtoński

2020

J Appl Genetics

View full text Add to dashboard Cite

Rapid progress in knowledge of the organization of the dog genome has facilitated the identification of the mutations responsible for numerous monogenic diseases, which usually present a breed-specific distribution. The majority of these diseases have clinical and molecular counterparts in humans. The affected dogs have thus become valuable models for preclinical studies of gene therapy for problems such as eye diseases, immunodeficiency, lysosomal storage diseases, hemophilia, and muscular dystrophy. Successful gene therapies in dogs have significantly contributed to decisions to run clinical trials for several human diseases, such as Leber's congenital amaurosis 2-LCA2 (caused by a mutation of RPE65), X-linked retinitis pigmentosa-XLRP (caused by mutation RPGR), and achromatopsia (caused by mutation of CNGB3). Promising results were also obtained for canine as follows: hemophilia (A and B), mucopolysaccharidoses (MPS I, MPS IIIB, MPS VII), leukocyte adhesion deficiency (CLAD), and muscular dystrophy (a counterpart of human Duchenne dystrophy). Present knowledge on molecular background of canine monogenic diseases and their successful gene therapies prove that dogs have an important contribution to preclinical studies.

show abstract

Leucocyte adhesion deficiency III in a mixed‐breed dog

Cited by 9 publications

References 32 publications

Recurrent bacterial pneumonia in Irish Wolfhounds: Clinical findings and etiological studies

Recurrent bacterial pneumonia in Irish Wolfhounds: Clinical findings and etiological studies

Optionen zur Therapie der felinen infektiösen Peritonitis – früher und heute

Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies

Contact Info

Product

Resources

About